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Purpose: The suppression of tumorigenicity 2 (ST2) has two main splice variants including 
a membrane bound (ST2) form, which activates the myeloid differentiation primary response 
88 (MyD88)/nuclear factor-kappa B (NF-κB) signaling pathway, and a secreted soluble form 
(sST2), which acts as a decoy receptor for ST2 ligand, interleukin (IL)-33. The IL-33/ST2 
axis is protective against obesity, insulin resistance, and type 2 diabetes (T2D). In humans, 
adipose tissue IL-33 displays distinct correlation profiles with glycated hemoglobin, ST2, 
and other immunometabolic mediators, depending on the glycemic health of the individuals. 
We determined whether adipose tissue ST2 displays distinct correlation profiles with immu-
nometabolic mediators and whether ST2 and/or IL-33 are correlated with intracellular 
signaling molecules.
Patients and Methods: A total of 91 adults with normal glycemia, prediabetes, and T2D 
were included. After measuring their anthropometric and biochemical parameters, subcuta-
neous adipose tissues were isolated and mRNA expression of biomarkers was measured.
Results: In individuals with normal glycemia, adipose tissue ST2 was directly correlated 
with chemokine (C-C motif) ligand (CCL)-2, CCL5, IL-12, fibrinogen-like protein 2 (FGL2) 
and interferon regulatory factor (IRF)-4, but inversely correlated with cytochrome C oxidase 
subunit 7A1. IL-33 and ST2 were directly correlated with tumor necrosis factor receptor- 
associated factor 6 (TRAF6), NF-κB, and nuclear factor of activated T-cells 5 (NFAT5). In 
individuals with prediabetes, ST2 was inversely correlated with IL-5, whereas IL-33 but not 
ST2 was directly correlated with MyD88 and NF-κB. In individuals with T2D, ST2 was 
directly correlated with CCL2, IL-1β, and IRF5. IL-33 and ST2 were directly correlated with 
MyD88, TRAF6, and NF-κB.
Conclusion: Adipose tissue ST2 and IL-33 show different correlation profiles with various 
immunometabolic biomarkers depending on the metabolic state of the individuals. Therefore, 
targeting the IL-33/ST2 axis might form the basis for novel therapies to combat metabolic 
disorders.
Keywords: obesity, prediabetes, type 2 diabetes, suppression of tumorigenicity 2, 
interleukin-33
Introduction
Adipose tissue inflammation plays a major role in the development of insulin resistance 
and type 2 diabetes (T2D). The suppression of tumorigenicity 2 (ST2) gene has two 
main splice variants; one encodes for a transmembrane isoform (ST2L), and the other 
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isoform encodes for a soluble and secreted protein (sST2).1 
ST2L confers the downstream functions of the ligand inter-
leukin (IL)-33, while sST2 serves as an antagonistic decoy 
receptor.2 ST2L is expressed by innate and adaptive immune 
cells, including monocytes, macrophages, dendritic cells, 
innate lymphoid cell (ILC)-2, B1 B-cells, T helper (Th)-2 
cells, T cytotoxic (Tc)-1 cells, T regulatory (Treg) cells, and 
Th9 cells.1,3-27 IL-33 can have a dual-function: acting extra-
cellularly as a cytokine (cleaved/mature IL-33), or intracel-
lularly as a nuclear factor (proteolytically uncleaved full- 
length IL-33).28 In this regard, IL-33 is constitutively 
expressed in the nucleus of certain cell types, including pre- 
adipocytes, adipocytes, endothelial cells and epithelial 
cells.29–31 The main function of intranuclear IL-33 is regula-
tion of gene expression.28 However, IL-33 is rapidly and 
passively released from cells in response to cell damage, 
hence, referred to as an “alarmin”. In addition, IL-33 can be 
secreted by activated immune cells, including monocytes/ 
macrophages,32–35 dendritic cells,36 and mast cells,34 and 
thus, play an important role in immune regulation.37 
Extracellular IL-33 interacts with ST2L forming a complex 
with the IL-1 receptor accessory protein (IL-1RAP), which 
signals via the myeloid differentiation primary response 88 
(MyD88)/interleukin-1 receptor-associated kinase 1 
(IRAK1)/tumor necrosis factor (TNF) receptor-associated 
factor 6 (TRAF6) intracellular signaling pathways. This 
leads to activation of mitogen-activated protein kinase 
(MAPK)/activator protein 1 (AP1) or nuclear factor-kappa 
B (NF-κB) transcription factors38,39 (Figure 1; previously 
published).40
Previous studies in animal models have demonstrated that 
the IL-33/ST2 axis is protective against obesity, insulin resis-
tance, and T2D.31,41,42 In addition, circulating IL-33 may con-
fer protective metabolic effects in humans, specifically, in 
individuals with normal-weight/glycemia but not in those 
with obesity and/or T2D.43 The mechanisms by which IL-33 
exerts protective metabolic effects include reduction of resistin 
expression,31 accumulation of protective Th2 cells and asso-
ciated cytokines, and polarization of resident macrophages 
toward a protective alternatively activated phenotype.31,41 In 
a recent study, we found no difference in the expression level of 
adipose tissue IL-33 or ST2 among individuals with normal 
glycemia, prediabetes and T2D. However, adipose tissue IL-33 
displayed distinct correlation profiles with overall glycemia, 
and related immunometabolic biomarkers, depending on 
whether the participants had normal glycemia, prediabetes or 
T2D. More specifically, adipose tissue IL-33 was inversely 
correlated with glycated hemoglobin (HbA1c), and directly 
correlated with adipose tissue ST2, in individuals with normal 
glycemia and in those with T2D and managed with glucose- 
lowering medications (T2D/med) but not in persons with 
prediabetes.44 This suggests an important dynamic relationship 
Figure 1 IL-33/ST2 signaling pathway. 
Note: Reprinted from Cytokine & Growth Factor Reviews, 50, Liu X, Xiao Y, Pan Y, Li H, Zheng SG, Su W, The role of the IL-33/ST2 axis in autoimmune disorders: Friend 
or foe?, 60–74, Copyright (2019), with permission from Elsevier.40
Hasan et al                                                                                                                                                            Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                           


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
between IL-33 and ST2 in the adipose tissue, which may 
influence overall glycemia; and importantly, its potential dys-
function during metabolic disease development, and its poten-
tial reversal with glucose-lowering medications.44 Therefore, 
we conducted this study to explore the correlation between 
adipose tissue ST2 and chemokines/cytokines, transcription 
factors and other signaling molecules in the adipose tissue of 
individuals with normal glycemia, prediabetes and T2D/med.
Patients and Methods
Study Participants
The study was approved by the Ethical Review Committee of 
Dasman Diabetes Institute, State of Kuwait, and was con-
ducted in accordance with the ethical principles of the 
Declaration of Helsinki. This work was conducted using sam-
ples obtained as part of the Adult Obesity Program (RA 2010- 
0003). For the current study, the inclusion criteria included 
adult volunteers (age ≥21 years), body mass index (BMI) 
≥18 kg/m2, lack of exercise regimen for at least one year, and 
having an overall glycemia in the normal (HbA1c <5.7%) or 
prediabetes (HbA1c 5.7–6.4%) range, or a diagnosis of T2D. 
The exclusion criteria included the presence of any disease/ 
consumption of medication in individuals with normal glyce-
mia, and treatment with any type of glucose-lowering medica-
tions in those with prediabetes. According to these criteria, the 
study included 91 adults between the ages of 23 and 72. All 
participants had provided written informed consent, and were 
grouped based on their HbA1c (in accordance with the 
American Diabetes Association criteria45) into three groups, 
namely normal glycemia (HbA1c <5.7%), prediabetes 
(HbA1c 5.7–6.4%; not on glucose-lowering medications) and 
T2D/med (a diagnosis of T2D; on any type of glucose- 
lowering medications) (Flowchart shown in Figure 2).45–47 
Comorbid health conditions included hypertension, dyslipide-
mia, cardiovascular disease, kidney disease and neuropathy 
(Table 1). Details of the types of prescribed medications 
taken by individuals with prediabetes and/or T2D are listed 
in Table 2.
Anthropometric and Laboratory 
Measurements
The participant’s body weight (kg) and height (to the nearest 
0.5 cm) were measured, and the BMI was calculated as weight/ 
height2 (kg/m2) and used as an overall index of adiposity. The 
waist and hip circumferences were measured using a flexible 
tape according to the guidelines of the International Diabetes 
Federation (IDF). After the participant exhaled, the waist 
circumference was measured on a horizontal plane at a point 
that was equally distant from the lowest rib and the upper 
border of the iliac crest. Hip circumference was measured on 
a horizontal plane at the maximum protuberance of the but-
tocks which parallels the ischiopubic symphysis in the front. 
The waist-to-hip ratio (WHR) was calculated by dividing the 
waist perimeter by the hip perimeter. The body composition, 
including body fat (%), soft lean mass (SLM) (%) and total 
body water (%), were measured using IOI 353 Body 
Composition Analyzer (Jawon Medical) (Table 1).
Fasting blood samples were obtained, and plasma glu-
cose, serum total cholesterol, triglycerides (TG), high- 
density lipoprotein (HDL) cholesterol were measured using 
the Siemens Dimension RXL chemistry analyser (Diamond 
Diagnostics, Holliston, MA, USA). Low-density lipoprotein 
(LDL) cholesterol was estimated. HbA1c was measured 
using VariantTM (Bio-Rad, Hercules, CA, USA). The white 
blood cell count was measured using XN-1000 Haematology 
Analyser (Sysmex, USA). C-reactive protein (CRP) was 
measured using commercially available Enzyme-Linked 
Immunosorbent Assay (ELISA) kits (BioVendor, USA). 
Insulin was measured using commercially available Iso- 
insulin ELISA kits (Mercodia, Uppsala, Sweden). 
Homeostatic Model Assessment of Insulin Resistance 
(HOMA-IR) was calculated using the following formula: 
glucose in mmol/L x insulin in mIU/mL/22.5 (Tables 1 and 




Real-time reverse-transcription polymerase chain reaction was 
conducted, as previously described.44,48 Briefly, cDNA sam-
ples (reverse transcribed from RNA samples) were amplified 
using TaqMan® Gene Expression Master Mix (Applied 
Biosystems, CA, USA) and gene-specific 20× TaqMan Gene 
Expression Assay (Applied Biosystems, CA, USA)54 using 
a 7500 Fast Real-Time PCR System (Applied Biosystems, 
CA, USA). Amplified glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) expression was used as an internal control. 
The comparative CT method was used to analyze the relative 
gene expression of various immunometabolic biomarkers 
using the formula 2-ΔΔCT whereby ΔΔCT = [CT gene of 
interest – CT endogenous control; ΔCT] – normal weight con-
trol with highest ΔCT. The relative mRNA fold expression for 
each specific gene was calculated by normalizing CT values to 
the endogenous control GAPDH (ΔCT) followed by 
Dovepress                                                                                                                                                           Hasan et al
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020:13                                         submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       



















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
normalizing ΔCT of each gene expression to the highest ΔCT of 
normal weight control. The assays IDs of the analyzed genes 
are shown in Supplementary Table 2.
Isolation of RNA from Subcutaneous 
Adipose Tissue
Human adipose tissues (~0.5 g) were collected from abdominal 
subcutaneous fat pads as described previously,44 and preserved 
in RNAlater or embedded in optimal cutting temperature com-
pound and stored at −80 °C. Total cellular RNA was purified 
using the RNeasy kit (Qiagen, Valencia, CA, USA) as per 
manufacturer’s instructions. The quantity and quality of the 
isolated RNA were determined using the Epoch™ 
Spectrophotometer System (BioTek, Winooski, VT, USA) 
and formaldehyde–agarose gel electrophoresis, respectively.
Statistical Methods
The non-parametric Spearman’s r test was used for the 
correlation analysis, and a heat-map of the correlations 
was generated. To compare between groups of data, the 
non-parametric Kruskal–Wallis test, as well as the Mann– 
Whitney test, were used. Correlations and group compar-
isons were conducted using the GraphPad Prism software 
(Version 8.0.2; San Diego, CA, USA). Analysis of covar-
iance and linear regression were conducted using the IBM 
SPSS software (Version 25; New York, USA). A P-value 
of <0.05 was considered statistically significant.
Participants 
Any disease or intake of 
any medication  
Normal glycemia 
HbA1c: <5.7% 
n = 21 
Prediabetes 
HbA1c: 5.7-6.4% 
n = 23 
Intake of any type of 
glucose-lowering 
medications 
Inclusion  Exclusion  
T2D diagnosis  
Taking any glucose-
lowering medications 
n = 47 
• Age ≥21 years 
• BMI ≥18 kg/m2
• Subcutaneous adipose samples 
• Lack of exercise regimen for 1 year 
Figure 2 Flowchart of inclusion and exclusion criteria.
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Results
Adipose Tissue ST2 Shows Distinct 
Correlation Profiles with Chemokines 
Depending on the Glycemic Status of the 
Individuals
We investigated the correlation between ST2 and various 
chemokines (chemokine (C-C motif ligand (CCL)-2, 
CCL5, CCL7, CCL8, CCL11, CCL15, CCL19, CCL20, 
(C-X-C motif) ligand (CXCL)-9 and CXCL10) in the 
adipose tissue of individuals with normal glycemia, pre-
diabetes and T2D/med. ST2 was directly correlated with 
CCL2 (r = 0.6, P = 0.0085, n = 18; after adjustment for 
age (r = 0.6, P = 0.01), gender (r = 0.6, P = 0.009) and 
BMI (r = 0.586, P = 0.013)) and CCL5 (r = 0.53, P = 0.04, 
n = 15; after adjustment for age (r = 0.49, P = 0.076), 
gender (r = 0.54, P = 0.048) and BMI (r = 0.54, P = 
0.048)) in the adipose tissue of individuals with normal 
glycemia but not in those with prediabetes. In individuals 
with T2D/med, ST2 showed a similar correlation profile to 
those with normal glycemia; in this regard, ST2 was 
directly correlated with CCL2 (r = 0.35, P = 0.03, n = 
39; after adjustment for age (r = 0.364, P = 0.02), gender 
(r = 0.372, P = 0.017) and BMI (r = 0.336, P = 0.032)) 
(Figure 4A and B; Heat-map shown in Figure 3). When 
the levels of these two chemokines were compared 
Table 1 Anthropometric, Biochemical and Metabolic Characteristics of the Study Groups
Participants Normal glycemia Prediabetes T2D/med *P-value
Total number (n) 21 23 47 -
Gender (%; n)
Female 43%; n=9 47%; n=11 43%; n=20 -
Male 57%; n=12 52%; n=12 57%; n=27 -
Age (years) 37 (24, 66) 43 (26, 71) 54 (23, 72) < 0.0001
Medication administrations (%) None 35% 96% -
Registered health conditions:
Dyslipidemia None 4% 19% -
Hypertension None 13% 40% -
Cardiovascular disease None 4% 2% -
Kidney disease None None 11% -
Neuropathy None None Not specified -
Body mass index (kg/m2) 30.1 ± 5.2 31.16 ± 5.54 31.3 ± 3.79 0.38
Waist-to-Hip ratio 0.88 (0.48, 1.07) (n = 20) 0.94 (0.68, 1.1) (n = 19) 0.94 (0.77, 2.34) (n = 37) 0.12
Body fat (%) 34.4 ± 6.5 (n = 20) 34.92 ± 6.7 (n = 18) 35.44 ± 5.59 (n = 37) 0.85
Soft lean mass (%) 59.97 ± 6.41 (n = 20) 59.45 ± 6.68 (n = 18) 58.96 ± 5.58 (n = 37) 0.85
Total body water (%) 47.25 ± 4.65 (n = 20) 46.88 ± 4.87 (n = 18) 46.53 ± 4.05 (n = 37) 0.87
SLM%-to-BF% ratio 1.64 (1.1, 3.7) (n = 20) 1.55 (1.1, 3.2) (n = 18) 1.58 (1.07, 3.19) (n = 37) 0.85
HbA1c (%) 5.3 (4.4, 5.6) (n = 20) 5.9 (5.7, 6.2) 8.1 (4.9, 12.3) < 0.0001
Fasting plasma glucose (mmol/L) 5 (4.4, 5.9) 5.3 (4.3, 6.4) 8.2 (4.6, 17.7) < 0.0001
Insulin (mU/L) 6.1 (4.9, 34.7) (n=15) 10.34 (4.32, 93.7) (n=16) 14.6 (3.57, 80.23) (n=38) § 0.08
HOMA-IR 1.46 (1.14, 7.6) (n=15) 2.21 (0.98, 22.9) (n=16) 5.57 (1.1, 26.3) (n=38) 0.0003
Total Chol (mmol/L) 4.87 (3.5, 6.3) 5.3 (3.9, 7) 4.63 (2.5, 8.5) (n = 46) 0.038
HDL Chol (mmol/L) 1.16 (0.88, 2.24) 1.3 (0.69, 1.85) 1.11 (0.6, 2) (n = 45) 0.18
Estimated LDL Chol (mmol/L) 2.99 ± 0.66 3.62 ± 0.75 2.8 ± 1.16 (n = 44) 0.003
Triglycerides (mmol/L) 0.79 (0.43, 2.93) 1.09 (0.42, 1.86) 1.39 (0.36, 7.63) (n = 46) 0.0009
Total Chol-to-HDL Chol ratio 3.7 (2.4, 5.6) 4.1 (3.1, 7.23) 3.97 (2, 9.43) (n=45) 0.41
CRP (µg/ml) 3.13 (0.91, 9.58) (n = 12) 3.85 (0.72, 8.14) (n = 16) 4.72 (0.94, 17.92) (n = 27) 0.4
White blood cell count (109/L) 5.7 ± 1.35 6.8 ± 2.17 (n = 21) 7.4 ± 2.1 (n = 45) 0.006
Notes: Data shown represent either the standard deviation of the mean or the median (min, max) as indicated; *Non-parametric Kruskal–Wallis test of the medians; §34% 
of participants were on insulin therapy. Copyright ©2019 Dis Markers. Adapted from Hasan A, Kochumon S, Al-Ozairi E, Tuomilehto J, Ahmad R. Association between 
adipose tissue interleukin-33 and immunometabolic markers in individuals with varying degrees of glycemia. Dis Markers. 2019.44 
Abbreviations: SLM, soft lean mass; BF, body fat; HbA1c, glycated hemoglobin; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; Chol, cholesterol; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; CRP, c-reactive protein; T2D/med, type 2 diabetes managed with glucose-lowering medications.
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between the three groups, it was found that individuals 
with prediabetes (median = 2.76, n = 19) had significantly 
(P = 0.009) higher levels of CCL5 compared to those with 
T2D/med (median = 1.87, n = 36). Moreover, individuals 
with T2D/med (median = 2.4, n = 42) had significantly (P 
= 0.02) higher levels of CCL2 compared to those with 
normal glycemia (median = 2, n = 21) (data not shown). 
The correlation between these chemokines and metabolic 
parameters are shown in Table 4.
Adipose Tissue ST2 Shows Distinct 
Correlation Profiles with Th1/Th2 
Cytokines and FGL2 Depending on the 
Glycemic Status of the Individuals
We investigated the correlation between ST2 and inflam-
matory and Th1 cytokines (IL-1β, TNF-α, IL-6, IL-8, 
IL-12A, IL-18, and IL-23A), Th2 cytokines (IL-5 and 
IL-13), regulatory cytokines (IL-10 and transforming 
growth factor-β) and fibrinogen-like protein 2 (FGL2), 
in the adipose tissue of individuals with normal glyce-
mia, prediabetes and T2D/med. ST2 was directly corre-
lated with IL-12 (r = 0.61, P = 0.03, n = 13; after 
adjustment for age (r = 0.61, P = 0.036), gender (r = 
0.73, P = 0.007) and BMI (r = 0.614, P = 0.034)) in the 
adipose tissue of individuals with normal glycemia. ST2 
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Table 3 A Comparison of the Parameters Between Two Groups 
of Participants with Different Metabolic States






Age (years) - P<0.0001 P=0.003




Insulin (mU/L) - P=0.018 -
HOMA-IR - P<0.0001 P=0.034
Total Chol (mmol/L) P=0.03 - P=0.018
Estimated LDL Chol 
(mmol/L)
P=0.008 - P=0.001
Triglycerides (mmol/L) - P=0.0007 P=0.0084
White blood cell 
count (109/L)
- P=0.0008 -
Notes: Non-parametric Mann–Whitney test was used to compare metabolic 
parameters between individuals with normal glycemia, prediabetes or T2D/med. 
Only significant P values are shown. 
Abbreviations: HbA1c, glycated hemoglobin; HOMA-IR, Homeostatic Model 
Assessment of Insulin Resistance; Chol, cholesterol; LDL, low-density lipoprotein; 
NL, normal glycemia; Predm, prediabetes; T2D/med, type 2 diabetes managed with 
glucose-lowering medications.
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was inversely correlated with IL-5 (r = −0.58, P = 0.03, 
n = 14; after adjustment for age (r = −0.57, P = 0.035), 
gender (r = −0.615, P = 0.02) and BMI (r = −0.73, P = 
0.003)) in the adipose tissue of individuals with predia-
betes. In individuals with T2D/med, ST2 was directly 
correlated with IL-1β (r = 0.61, P = 0.0005, n = 28; 
after adjustment for age (r = 0.48, P = 0.006), gender 
(r = 0.46, P = 0.009) and BMI (r = 0.423, P = 0.018)) 
(Figure 5A–C; Heat-map shown in Figure 3). In addi-
tion, ST2 was directly correlated with FGL2 (r = 0.56, 
P = 0.015, n = 18; after adjustment for age (r = 0.573, 
P = 0.016), gender (r = 0.548, P = 0.023) and BMI (r = 
0.61, P = 0.009)) in the adipose tissue of individuals 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































A Normal glycemia B Prediabetes 
T2D/medC
Figure 3 Heat-map of the correlations found in individuals with normal glycemia (A), prediabetes (B), and T2D/med (C). 
Abbreviations: CCL, chemokine (C-C motif) ligand; IL, interleukin; ST2, suppression of tumorigenicity 2; FGL2, fibrinogen-like protein 2; COX7A1, cytochrome C oxidase 
subunit 7A1; MyD88, myeloid differentiation primary response 88; TRAF6, tumor necrosis factor receptor-associated factor 6; NFκB, nuclear factor-kappa B; IRF, interferon 
regulatory factor; NFAT5, nuclear factor of activated T-cells 5.
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Figure 3). Of note, there was no significant difference in 
the level of IL-12, IL-5, IL-1β, or FGL2 between the 
three groups (data not shown). The correlation between 
these cytokines and FGL2 and metabolic parameters are 
shown in Table 4.
Adipose Tissue ST2 Shows Distinct 
Correlation Profiles with Mitochondrial 
Protein COX7A1 Depending on the 
Glycemic Status of the Individuals
We investigated the correlation between ST2 and tran-
scriptional coregulators and mitochondrial proteins (PR 
domain containing 16 (PRDM16), uncoupling protein 1 
(UCP1) and cytochrome C oxidase subunit 7A1 
(COX7A1)) in the adipose tissue of individuals with 
normal glycemia, prediabetes and T2D/med. ST2 was 
inversely correlated with COX7A1 (but not UCP1 or 
PRDM16) in the adipose tissue of individuals with nor-
mal glycemia (r = −0.54, P = 0.02, n = 18; after 
adjustment for age (r = −0.55, P = 0.023), gender (r = 
−0.555, P = 0.021) and BMI (r = −0.535, P = 0.027)) 
but not in those with prediabetes or T2D/med 
(Figure 6B; Heat-map shown in Figure 3). Of note, the 
expression of adipose tissue COX7A1 was significantly 
(P = 0.046) higher in individuals with prediabetes (med-
ian = 2.99, n = 22) compared to those with normal 
glycemia (median = 2, n = 21) (data not shown). The 
correlation between COX7A1 and metabolic parameters 
are shown in Table 4.
Adipose Tissue IL-33 and ST2 Show 
Distinct Correlation Profiles with 
MyD88/TRAF6/NF-κB Depending on the 
Glycemic Status of the Individuals
We assessed the correlation between IL-33 or ST2 and 
the signaling molecules MyD88, TRAF6, and NF-κB in 
the adipose tissue of individuals with normal glycemia, 
prediabetes and T2D/med. In individuals with normal 
glycemia, IL-33 was directly correlated with TRAF6 
(r = 0.63, P = 0.002, n = 21; after adjustment for age 
(r = 0.67, P = 0.001), gender (r = 0.64, P = 0.003) and 
BMI (r = 0.65, P = 0.002)) and NF-κB (r = 0.5, P = 
0.02, n = 21; after adjustment for age (r = 0.48, P = 
0.034), gender (r = 0.48, P = 0.032) and BMI (r = 0.85, 
P = 0.068)) but not MyD88. Similarly, ST2 was directly 
correlated with TRAF6 (r = 0.51, P = 0.03, n = 18; after 
adjustment for age (r = 0.513, P = 0.035), gender (r = 
0.5, P = 0.042) and BMI (r = 0.5, P = 0.04)) and NF-κB 
(r = 0.52, P = 0.03, n = 18; after adjustment for age (r = 
0.523, P = 0.031), gender (r = 0.55, P = 0.023) and BMI 
(r = 0.522, P = 0.032)) but not MyD88. In individuals 
with prediabetes, IL-33 was directly correlated with 
































NL: r = 0.6, P = 0.0085, n = 18
T2D: r = 0.35, P = 0.03, n = 39




Figure 4 ST2 displays distinct correlation profiles with chemokines in the adipose tissue of individuals with normal glycemia, prediabetes and T2D/med. (A) Direct 
correlation between ST2 and CCL2 in the adipose tissue of individuals with normal glycemia (n = 18) and T2D/med (n = 39). (B) Direct correlation between ST2 and CCL5 
in the adipose tissue of individuals with normal glycemia (n = 15). 
Abbreviations: ST2, suppression of tumorigenicity 2; CCL, chemokine (C-C motif) ligand; NL, normal glycemia; T2D/med, type 2 diabetes managed with glucose-lowering 
medications.
Hasan et al                                                                                                                                                            Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                           


















































































Powered by TCPDF (www.tcpdf.org)







































































































































































































































































































































































































































































































































































































































































Dovepress                                                                                                                                                           Hasan et al
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020:13                                         submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       



















































































Powered by TCPDF (www.tcpdf.org)







































































































































































































































































































































































































































































































































































































































































































































































































































































Hasan et al                                                                                                                                                            Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                           


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
MyD88 (r = 0.44, P = 0.036, n = 23; after adjustment for 
age (r = 0.45, P = 0.037), gender (r = 0.46, P = 0.033) 
and BMI (r = 0.49, P = 0.022)) and NF-κB (r = 0.43, 
P = 0.04, n = 23; after adjustment for age (r = 0.46, P = 
0.03), gender (r = 0.43, P = 0.045) and BMI (r = 0.475, 
P = 0.026)) but not TRAF6. No correlation was observed 
between ST2 and down-stream signaling molecules. In 
individuals with T2D/med, IL-33 was directly correlated 
with MyD88 (r = 0.31, P = 0.04, n = 44; after adjust-
ment for age (r = 0.29, P = 0.058), gender (r = 0.32, P = 
0.038) and BMI (r = 0.285, P = 0.064)), TRAF6 (r = 
0.52, P = 0.0002, n = 47; after adjustment for age (r = 
0.48, P = 0.001), gender (r = 0.56, P = 0.000) and BMI 
(r = 0.532, P = 0.000)) and NF-κB (r = 0.45, P = 0.001, 
n = 47; after adjustment for age (r = 0.463, P = 0.001), 
gender (r = 0.483, P = 0.001) and BMI (r = 0.436, P = 
0.002)). Similarly, ST2 was directly correlated with 
MyD88 (r = 0.35, P = 0.02, n = 42; after adjustment 
for age (r = 0.343, P = 0.028), gender (r = 0.353, P = 
0.024) and BMI (r = 0.4, P = 0.01)), TRAF6 (r = 0.38, 
P = 0.01, n = 43; after adjustment for age (r = 0.36, P = 
0.02), gender (r = 0.373, P = 0.015) and BMI (r = 0.38, 












































NL: r = 0.61, P = 0.03, n = 13 Predm: r = −0.58, P = 0.03, n = 14






Figure 5 ST2 displays distinct correlation profiles with cytokines in the adipose tissue of individuals with normal glycemia, prediabetes and T2D/med. (A) Direct correlation 
between ST2 and IL-12A in the adipose tissue of individuals with normal glycemia (n = 13). (B) Inverse correlation between ST2 and IL-5 in the adipose tissue of individuals 
with prediabetes (n = 14). (C) Direct correlation between ST2 and IL-1β in the adipose tissue of individuals with T2D/med (n = 28). 
Abbreviations: ST2, suppression of tumorigenicity 2; IL, interleukin; NL, normal glycemia; Predm, prediabetes; T2D/med, type 2 diabetes managed with glucose-lowering 
medications.
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P = 0.013)) and NF-κB (r = 0.36, P = 0.02, n = 43; after 
adjustment for age (r = 0.35, P = 0.023), gender (r = 
0.352, P = 0.022) and BMI (r = 0.393, P = 0.01)) 
(Figure 7A–F; Heat-map shown in Figure 3). There was 
no significant difference in the level of adipose tissue 
MyD88, TRAF6 or NF-κB between the three groups 
(data not shown).
Adipose Tissue IL-33 and ST2 Show 
Distinct Correlation Profiles with IRFs 
and NFAT5 Depending on the Glycemic 
Status of the Individuals
We assessed whether IL-33 or ST2 were correlated with 
interferon regulatory factors (IRF)-3, IRF4 and IRF5, and 
additionally, nuclear factor of activated T-cells 5 (NFAT5). 
ST2 was directly correlated with IRF4 (r = 0.6, P = 0.019, n = 
15; after adjustment for age (r = 0.6, P = 0.022), gender (r = 
0.58, P = 0.03) and BMI (r = 0.61, P = 0.02)) in individuals 
with normal glycemia but not in those with prediabetes. In 
individuals with T2D/med, ST2 was directly correlated with 
IRF5 (r = 0.4, P = 0.008, n = 42; after adjustment for age (r = 
0.4, P = 0.009), gender (r = 0.4, P = 0.009) and BMI (r = 
0.39, P = 0.011)) (Figure 8A and B; Heat-map shown in 
Figure 3). Overall, there was no correlation between ST2 and 
IRF3, and between IL-33 and IRF3, IRF4 or IRF5. When the 
levels of IRF3, IRF4 and IRF5 were compared between the 
three groups, it was found that individuals with T2D/med had 
higher levels (P = 0.05, median = 2.7, n = 42) of IRF3 
compared to those with prediabetes (median = 2.3, n = 21); 
and similarly, had significantly (P = 0.04, median = 2.9, n = 
45) higher levels of IRF5 compared to those with prediabetes 
(median = 2.16, n = 22). Moreover, individuals with T2D/ 
med (median = 4.14, n = 40) had significantly higher levels of 
IRF4 compared to those with normal glycemia (P = 0.023, 
median = 2.7, n = 16) and prediabetes (P = 0.021, median = 
2.98, n = 21) (data not shown).
Moreover, IL-33 was directly correlated with NFAT5 
in individuals with normal glycemia (r = 0.66, P = 
0.001, n = 21; after adjustment for age (r = 0.67, P = 
0.001), gender (r = 0.655, P = 0.002) and BMI (r = 
0.685, P = 0.001)) but not in those with prediabetes or 







































Figure 6 ST2 displays distinct correlation profiles with FGL2 and COX7A1 in the adipose tissue of individuals with normal glycemia, prediabetes and T2D/med. (A) Direct 
correlation between ST2 and FGL2 in the adipose tissue of individuals with normal glycemia (n = 18). (B) Inverse correlation between ST2 and COX7A1 in the adipose 
tissue of individuals with normal glycemia (n = 18). 
Abbreviations: ST2, suppression of tumorigenicity 2; FGL2, fibrinogen-like protein 2; COX7A1, cytochrome C oxidase subunit 7A1; NL, normal glycemia; T2D/med, type 
2 diabetes managed with glucose-lowering medications.
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T2D/med. Similarly, ST2 was directly correlated with 
NFAT5 (r = 0.65, P = 0.003, n = 18; after adjustment 
for age (r = 0.65, P = 0.005), gender (r = 0.69, P = 
0.002) and BMI (r = 0.68, P = 0.003)) in individuals 
with normal glycemia but not in those with prediabetes 
or T2D/med (Figure 9A and B; Heat-map shown in 
Figure 3). There was no difference in the level of 
NFAT5 between the three groups (data not shown). 
The correlation between these biomarkers and metabolic 
parameters are shown in Table 4.




































































































T2D: r = 0.35, P = 0.02, n = 42
NL: r = 0.51, P = 0.03, n = 18
T2D: r = 0.38, P = 0.01, n = 43
NL: r = 0.52, P = 0.03, n = 18




Predm: r = 0.44, P = 0.036, n = 23 
T2D: r = 0.31, P = 0.04, n = 44
A
NL: r = 0.63, P = 0.002, n = 21
T2D: r = 0.52, P = 0.0002, n = 47
C
NL: r = 0.5, P = 0.02, n = 21
Predm: r = 0.43, P = 0.04, n = 23





Figure 7 IL-33 and ST2 display distinct correlation profiles with MyD88/TRAF6/NF-κB in the adipose tissue of individuals with normal glycemia, prediabetes and T2D/med. 
(A) Direct correlation between IL-33 and MyD88 in the adipose tissue of individuals with prediabetes (n = 23) and T2D/med (n = 44). (B) Direct correlation between ST2 
and MyD88 in the adipose tissue of individuals with T2D/med (n = 42). (C) Direct correlation between IL-33 and TRAF6 in the adipose tissue of individuals with normal 
glycemia (n = 21) and T2D/med (n = 47). (D) Direct correlation between ST2 and TRAF6 in the adipose tissue of individuals with normal glycemia (n = 18) and T2D/med (n 
= 43). (E) Direct correlation between IL-33 and NF-κB in the adipose tissue of individuals with normal glycemia (n = 21), prediabetes (n = 23) and T2D/med (n = 47). (F) 
Direct correlation between ST2 and NF-κB in the adipose tissue of individuals with normal glycemia (n = 18) and T2D/med (n = 43). 
Abbreviations: IL, interleukin; ST2, suppression of tumorigenicity 2; MyD88, myeloid differentiation primary response 88; TRAF6, tumor necrosis factor receptor 
-associated factor 6; NF-κB, nuclear factor-kappa B; NL, normal glycemia; Predm, prediabetes; T2D/med, type 2 diabetes managed with glucose-lowering medications.
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Figure 8 ST2 displays distinct correlation profiles with IRFs in the adipose tissue of individuals with normal glycemia, prediabetes and T2D/med. (A) Direct correlation between ST2 
and IRF4 in the adipose tissue of individuals with normal glycemia (n = 15). (B) Direct correlation between ST2 and IRF5 in the adipose tissue of individuals with T2D/med (n = 42). 
Abbreviations: ST2, suppression of tumorigenicity 2; IRF, interferon regulatory factor; NL, normal glycemia; T2D/med, type 2 diabetes managed with glucose-lowering medications.





































Figure 9 IL-33 and ST2 display distinct correlation profiles with NFAT5 in the adipose tissue of individuals with normal glycemia, prediabetes and T2D/med. (A) Direct correlation between IL-33 
and NFAT5 in the adipose tissue of individuals with normal glycemia (n = 21). (B) Direct correlation between ST2 and NFAT5 in the adipose tissue of individuals with normal glycemia (n = 18). 
Abbreviations: ST2, suppression of tumorigenicity 2; IL, interleukin; NFAT5, nuclear factor of activated T-cells 5; NL, normal glycemia; T2D/med, type 2 diabetes managed with glucose- 
lowering medications.
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Discussion
Previous studies using animal models have demonstrated 
that the IL-33/ST2 axis is involved in protection against 
obesity, insulin resistance, and T2D.31,41,42 Recently, we 
reported that adipose tissue IL-33 displays distinct correla-
tion profiles with HbA1c, ST2 and related immunometa-
bolic biomarkers, depending on whether the participants 
had normal glycemia, prediabetes or T2D.44 In the present 
study, we assessed whether ST2 displays distinct correla-
tion profiles with chemokines/cytokines, mitochondrial 
proteins, and signaling molecules, in the adipose tissue 
of individuals with normal glycemia, prediabetes and 
T2D/med.
Chemokines, a family of low molecular weight cyto-
kines, play a key role in the trafficking of leukocytes to 
areas of inflammation and in leukocyte activation. 
Generally, the chemokine system functions to maintain 
homeostasis or to induce inflammation.49 In our study, indi-
viduals with T2D/med had significantly higher levels of 
circulating white blood cells (WBCs) compared to those 
with normal glycemia. Since there was no difference in the 
BMI between the groups, this suggests that individuals with 
T2D have an increased overall inflammatory status regard-
less of adiposity. Moreover, individuals with T2D/med had 
higher levels of adipose tissue CCL2 when compared to 
those with normal glycemia. This is expected since chemo-
kines, particularly CCL2, promote the infiltration of mono-
cytes into the adipose tissue where they differentiate into pro- 
inflammatory macrophages and promote insulin 
resistance.50,51
Importantly, ST2 displayed distinct correlation profiles 
with chemokines in the adipose tissue of individuals with 
normal glycemia, prediabetes and T2D/med. ST2 was 
directly correlated with CCL2 and CCL5 in the adipose 
tissue of individuals with normal glycemia; whereas no 
such correlation was observed in those with prediabetes. In 
fact, individuals with prediabetes showed a direct correla-
tion between CCL5 and the BMI, waist circumference, 
insulin and HOMA-IR. This is not surprising since CCL5 
participates in adipose tissue inflammation by recruiting 
monocytes and exerting anti-apoptotic effects on 
macrophages,52 which leads to metabolic dysfunction. 
Interestingly, however, individuals with prediabetes 
showed an inverse correlation between CCL2 and insulin 
and TG, and a direct correlation with LDL. In individuals 
with T2D/med, ST2 was directly correlated with CCL2; 
a similar finding to that found in individuals with normal 
glycemia. The direct correlation between ST2 and CCL2 
(and CCL5 in individuals with normal glycemia) may 
suggest an ST2-related protective mechanism in indivi-
duals with normal glycemia and T2D/med, with the latter 
possibly being due to glucose-lowering medications. Since 
the IL-33/ST2 axis is considered metabolically protective, 
the observed correlation between ST2 and chemokines in 
individuals with normal glycemia and T2D/med might be 
a sign of increased recruitment of anti-inflammatory ST2+ 
immune cells (mainly Th2 cells, alternatively activated 
macrophages, and regulatory T-cells), as opposed to pro- 
inflammatory cells, as an attempt to dampen inflammation.
Adipose tissue expansion and hypertrophic adipocytes 
leads to the secretion of pro-inflammatory cytokines 
including IL-6, IL-1β and TNF-α. These cytokines down-
regulate insulin sensitivity via activation of pro- 
inflammatory signaling and inhibition of insulin receptor 
signaling.53 Since ST2 may confer protective metabolic 
effects, we assessed its correlation with pro-inflammatory 
cytokines. ST2 was directly correlated with IL-1β, an 
inflammatory cytokine that was directly correlated with 
the BMI and waist circumference, in individuals with 
T2D/med. No such correlation was observed between 
ST2 and IL-1β, IL-6 or TNF-α in individuals with predia-
betes (or normal glycemia).
Studies using animal models suggest that Th1/Tc1 cells 
are involved in the attraction and differentiation of pro- 
inflammatory macrophages, while Th2 and Treg cells are 
protective against adipose tissue inflammation.54–56 We 
found that ST2 was directly correlated with IL-12 in the 
adipose tissue of individuals with normal glycemia. This 
may indicate an increase in the recruitment of ST2+ 
immune cells in the presence of IL-12. Interestingly, how-
ever, ST2 was inversely correlated with IL-5 (a down-
stream Th2 cytokine of IL-33/ST2 interaction) in 
individuals with prediabetes. It was previously shown 
that the IL-33/ST2 axis induces the production of Th2 
cytokines, mainly IL-5 and IL-13,57 and is involved in 
Treg cell responses,58–60 which is protective against meta-
bolic inflammation. Importantly, we previously reported 
a lack of correlation between ST2 and IL-33 in individuals 
with prediabetes.44 Taken together, these findings may 
suggest a dysfunction in the regulatory mechanism of the 
IL-33/ST2 axis, whereby a lack of concomitant increase in 
IL-33 and ST2 appears to be associated with a decrease in 
IL-5. Intriguingly, however, while IL-5 was inversely cor-
related with fasting glucose, which is in keeping with the 
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protective role of Th2 cytokines,54–56 it was directly cor-
related with WBCs in these individuals.
In contrast, people with T2D/med showed no correlation 
between ST2 and IL-5, however, this Th2 cytokine was 
directly (but weakly) correlated with fasting glucose. Taking 
into consideration our previous work where we found a direct 
correlation between IL-33 and ST2 in individuals with T2D/ 
med (which is similar to that found in those with normal 
glycemia),44 the association between IL-5 and fasting glucose 
may suggest a protective response. It may also suggest that the 
observed correlations between IL-5 and fasting glucose is 
distinct from the IL-33/ST2 axis, at least in individuals with 
T2D/med. Our previous work showed similar findings with IL- 
33 whereby no correlation was observed between IL-5 and IL- 
33 in the adipose tissue of individuals with normal glycemia, 
prediabetes or T2D/med.44 As a Th2 cytokine, IL-5 is gener-
ally regarded as metabolically protective; indeed, IL-5 was 
inversely correlated with HOMA-IR, TG and WBCs in indi-
viduals with normal glycemia. However, adipose tissue IL-5 
was also inversely correlated with SLM (%) and directly 
correlated with body fat (%) in these individuals.
In addition, we assessed whether adipose tissue ST2 
was correlated with FGL2, which is a protein that pro-
motes regulatory T cell function, suppresses Th1 cell 
responses, enhances Th2 skewing, and downregulates anti-
gen presentation.61–65 We found that ST2 was directly 
correlated with FGL2 in the adipose tissue of individuals 
with normal glycemia; although FGL2 was not correlated 
with the BMI, it was inversely correlated with the WHR in 
these individuals. There was no correlation between ST2 
and FGL2 in individuals with prediabetes or T2D/med. 
However, in individuals with T2D/med, FGL2 was 
directly correlated with SLM (%) and inversely correlated 
with body fat (%). Similarly, we previously showed that 
IL-33 was directly correlated with FGL2 in individuals 
with normal glycemia and T2D/med but not in those 
with prediabetes. Overall, FGL2 appears to be metaboli-
cally protective in individuals with normal glycemia and 
T2D/med. These findings may support the notion that the 
IL-33/ST2 axis promotes immune regulation.44
Subcutaneous white adipose tissue can convert to a brown- 
like “beige” adipose,66,67 which may facilitate 
thermogenesis.66,67 Both white and brown adipose tissue con-
tain innate immune cells, including macrophages, eosinophils 
and ILC2s, which play a role in white adipose browning.68 The 
transcriptional coregulator PRDM16 and mitochondrial pro-
teins UCP1 and COX7A1 are involved in beiging of adipose 
tissue.67,69-74 In this study, we found that ST2, although not 
correlated with UCP1 or PRDM16, was inversely correlated 
with COX7A1 in individuals with normal glycemia only. 
When COX7A1 was assessed for correlations with metabolic 
parameters, none were found in individuals with normal gly-
cemia or prediabetes; however, a direct correlation was 
observed between COX7A1 and HDL in patients with T2D/ 
med. Interestingly, the expression of adipose tissue COX7A1 
was significantly higher in individuals with prediabetes com-
pared to those with normal glycemia. Previous studies have 
shown that the level of COX7A1 is substantially higher in 
adipose tissue from mice fed a high fat diet,75 which suggests 
its association with gluco-metabolic disease. Therefore, the 
inverse correlation between ST2 and COX7A1 in our study 
may indicate another mechanism by which ST2 confers pro-
tective metabolic effects.
Extracellular mature IL-33 interacts with ST2L forming 
a complex with the IL-1RAP, which signals via the MyD88/ 
TRAF6 intracellular signaling pathway. This leads to activa-
tion of MAPK/AP1 or NF-κB transcription factors.38,39 Here, 
we found that both IL-33 and ST2 were directly correlated with 
downstream signaling molecules TRAF6 and NF-κB but not 
MyD88 in individuals with normal glycemia; interestingly, 
MyD88 was inversely correlated with HbA1c in these indivi-
duals. In contrast, in individuals with prediabetes, IL-33 was 
directly correlated with MyD88 and NF- κB but not TRAF6, 
and importantly, no correlation was observed between ST2 and 
any of the signalling molecules; moreover, TRAF6 was inver-
sely correlated with WHR, waist circumference and insulin, 
while NF-κB was directly correlated with HbA1c in these 
individuals. In individuals with T2D/med, both IL-33 and 
ST2 were directly correlated with TRAF6, NF-κB and 
MyD88; in addition, TRAF6 and NF-κB were both inversely 
correlated with body fat (%) and directly correlated with SLM 
(%), while TRAF6 was inversely correlated with HbA1c in 
these individuals.
Our data suggest that IL-33 correlation with MyD88 is 
restricted to individuals with prediabetes and T2D/med, 
and that in the latter, ST2 is additionally correlated with 
MyD88. Previous studies have shown that the binding of 
IL-33 to membrane ST2L can lead to its internalization 
with the receptor.76,77 Given that related receptors such as 
toll-like receptor 4 (TLR4) can signal via a MyD88-depen-
dent or independent pathway,78 it may be possible to 
hypothesize that, in the setting of normal glycemia, adi-
pose tissue IL-33 may induce ST2 internalization in 
response to TLR4 activation, which may cause a switch 
to the MyD88-independent pathway. This may explain the 
lack of correlation between IL-33 (as well as ST2) and 
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MyD88 in individuals with normal glycemia but not in 
those with metabolic disease. Therefore, our findings sug-
gest that ST2 may signal via a MyD88-independent path-
way leading to TRAF6/NF-κB activation and/or resolution 
of inflammation in individuals with normal glycemia, and 
its possible restoration (at least partially) with glucose- 
lowering medications in individuals with T2D/med. 
Moreover, intracellular IL-33 may associate with 
a critical cofactor in the nucleus forming a complex, 
which may then interact with a network of transcriptional 
regulators promoting the activity of NF-κB and its induc-
tion of genes.
In our previous work, we found a direct correlation 
between IL-33 and ST2 in individuals with normal glycemia 
and T2D/med but not in those with prediabetes.44 The direct 
correlation between IL-33 and ST2 may reflect a positive feed-
back loop in which enhanced expression of IL-33 induces 
a concomitant increase in ST2 expression,44 which in turn 
acts as a negative regulator of the MyD88-dependent TLR4 
signaling pathway leading to a MyD88-independent pathway. 
Therefore, it may be possible that ST2, acting as a negative 
regulator of TLR4 signaling, may promote a MyD88- 
independent pathway. Individuals with T2D/med showed 
a similar profile to those with normal glycemia (except for 
MyD88), which may be explained by the fact that these 
patients were on glucose-lowering medications which may 
have partially restored the IL-33/ST2 regulatory function in 
the adipose tissue. In individuals with prediabetes, the lack of 
correlation between ST2 and MyD88/TRAF6/NF-κB shown 
in this study, taken together with our previous work showing 
a lack of a correlation between ST2 and IL-33,44 may suggest 
a dysfunction in the IL-33/ST2 signaling pathway. 
Additionally, we hypothesize that ST2, in the absence of 
a positive feedback loop with IL-33, may prove to be pro- 
inflammatory, and that IL-33 may regulate ST2 expression.
IRFs are key transcription factors involved in the innate 
immune response and other physiological functions.79–81 Here, 
we assessed whether IL-33 and ST2 display distinct correlation 
profiles with IRFs in the adipose tissue of individuals with 
normal glycemia, prediabetes and T2D/med. ST2 was directly 
correlated with IRF4 in individuals with normal glycemia and 
with IRF5 in individuals with T2D/med. IRF4 has been shown 
to inhibit IRF5 activity by competing with IRF5 for its inter-
action with MyD88.82 In this study, a correlation was found 
between ST2 and MyD88, however, this correlation was lim-
ited to individuals with T2D/med. Therefore, ST2 signaling 
may activate IRF4 via a MyD88-independent pathway in the 
normal state, leading to inhibition of IRF5 activity and thus 
minimizing inflammatory responses. The correlation between 
ST2 and MyD88 and IRF5 in individuals with T2D/med but 
not in those with prediabetes may suggest a pathway that 
occurs specifically in established T2D, or some other un- 
known effect of glucose-lowering medications. When IRFs 
were assessed for correlations with metabolic parameters, 
IRF4 and IRF5 were found to be directly correlated with 
body fat (%) and inversely correlated with SLM (%) in indi-
viduals with prediabetes. In patients with T2D/med, IRF4 was 
directly correlated with WBCs, while IRF5 was directly corre-
lated with waist circumference.
Previous studies have demonstrated that an extensive meta-
bolic remodeling of white adipose tissue precedes the infiltra-
tion of inflammatory cells as well as the overt decrease in 
mitochondrial abundance. These metabolic changes in adipo-
cytes involves alterations in glucose and lipid pathways, which 
promote fat storage and prevent excessive lipid oxidation, and 
are also associated with osmotic stress and adipocyte 
inflammation.75 The transcription factor NFAT5, which is 
expressed by almost all cells, is activated in response to osmo-
tic stress83 and regulates the expression of osmoprotective 
genes.84 In this study, we assessed whether IL-33 and ST2 
were correlated with NFAT5 in the adipose tissue. Our data 
showed that both IL-33 and ST2 were directly correlated with 
NFAT5 in the adipose tissue of individuals with normal glyce-
mia but not in those with prediabetes or T2D/med. 
Interestingly, NFAT5 was inversely correlated with body fat 
(%) and directly correlated with SLM (%) in individuals with 
T2D/med.
NFAT5 has a highly conserved nuclear localization 
signal sequence motif which plays an important role in 
nuclear translocation. When cytosolic NFAT5 is activated 
by osmotic stress, it translocates to the nuclei where it 
regulates osmoprotective and inflammatory genes such as 
CCL2 and TNF-α.85 Indeed, NFAT5 has been shown to 
bind to TNF-α and lymphotoxin-β promoter, suggesting 
that NFAT5 plays other roles in immune cells, especially 
T-cells.86 In our study, since the observed correlation 
between NFAT5 and IL-33/ST2 was restricted to indivi-
duals with normal glycemia, it may be possible to 
hypothesize that in the presence of osmotic stress (being 
an early metabolic derangement in adipocytes), NFAT5 
activation may regulate genes involved in the IL-33/ST2 
axis leading to favorable metabolic outcome. Depending 
on partner proteins, NFATs can either enhance immune 
responses or induce immune tolerance.87 As NFATs are 
involved in diverse molecular interactions, they are tightly 
regulated by post-translational modifications in the 
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normal state.88 In response to osmotic stress, NFAT5 is 
activated by p38/MAPK signaling and regulates the 
expression of osmoprotective genes required for normal 
function.84 In addition, since NFAT5 is expressed by 
activated T-cells,83 it may be possible that NFAT5 upre-
gulates gene transcription of IL-33 during T cell activa-
tion. Indeed, a previous study had identified two 
regulatory regions upstream of the IL-33 transcription 
site that contain NFAT binding sites, and it is thought 
that IL-33, in addition to having dual functions (extracel-
lular and intranuclear), possesses dual pathways that reg-
ulate its expression.89 In addition, it may be possible that 
NFAT5 has some other function that is independent of 
osmostress.90 Future studies are required to investigate 
the relationship between NFAT5 and the IL-33/ST2 axis 
in the context of obesity and T2D.
Conclusion
Adipose tissue ST2 and IL-33 show distinct correlation 
profiles with various immunometabolic biomarkers 
depending on the metabolic state of the individuals. 
Therefore, the IL-33/ST2 axis may play a regulatory role 
in adipose tissue inflammation. Importantly, a dysfunction 
in the regulatory mechanism of the IL-33/ST2 axis may 
lead to metabolic disorders, which might be partially 
restored by glucose-lowering medications. Our observa-
tions have important implications for understanding the 
immunometabolic effects of the IL-33/ST2 axis and sug-
gest that targeting this axis could form the basis for novel 
therapies to combat metabolic disorders.
Study Limitations
This study has some limitations; firstly, the study was 
a single center study with a small sample size, thereby 
increasing the margin of error; secondly, the group with 
T2D included individuals along a wide range of spectrum 
with regards to several factors; these include duration and 
type of T2D (eg obesity-associated versus older age 
onset), type and dosage of glucose-lowering medications, 
different medications taken for comorbid health condi-
tions, duration of medication treatments, and the level of 
glycemic control. With regards to the latter, some patients 
with T2D/med did not have adequate glycemic control, 
which may have affected the data. Therefore, a much 
larger multi-center study is required to confirm these find-
ings and to directly evaluate the effect of medications.
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